Benzinga · Aug 4, 2026
Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $18
Wells Fargo analyst Benjamin Burnett maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight and lowers the price target from $20 to $18.
KR
NASDAQ · KROS
Keros Therapeutics, Inc.
Healthcare · Biotechnology
$11.08
Down-$0.02 (-0.18%)
Updated Sep 1, 2026, 5:15 PM
SID Score
6.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 878.88M
- P/E ratio
- 13.67
- Dividend yield
- 0.00%
- 52-week range
- $9.69 – $12.65
- Volume
- 179.96K
- Avg. volume
- 987.56K
Price performance
KROS price history
1M range · 21 trading sessions · Daily adjusted prices
KROS closed at $11.08 after 21 trading sessions, up 9.59% for the selected period.
- Last close
- $11.08
- Period change
- +9.59%
- Period low
- $10.00
- Period high
- $11.68
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 31, 2026 | $10.93 | $11.195 | $10.76 | $11.08 | 179.96K |
| Aug 28, 2026 | $11.15 | $11.16 | $10.58 | $11.03 | 328.29K |
| Aug 27, 2026 | $11.09 | $11.475 | $11.01 | $11.23 | 127.58K |
| Aug 26, 2026 | $11.66 | $11.66 | $11.08 | $11.12 | 113.6K |
| Aug 25, 2026 | $10.83 | $11.71 | $10.83 | $11.68 | 200.32K |
| Aug 24, 2026 | $11.12 | $11.12 | $10.72 | $10.78 | 217.08K |
| Aug 21, 2026 | $10.96 | $11.09 | $10.805 | $11.03 | 157.51K |
| Aug 20, 2026 | $11.09 | $11.10 | $10.55 | $10.95 | 203.07K |
| Aug 19, 2026 | $10.63 | $11.17 | $10.63 | $11.10 | 152.15K |
| Aug 18, 2026 | $10.38 | $10.67 | $10.12 | $10.61 | 256.15K |
| Aug 17, 2026 | $10.05 | $10.51 | $10.00 | $10.48 | 221.51K |
| Aug 14, 2026 | $10.59 | $10.59 | $10.018 | $10.10 | 315.28K |
| Aug 13, 2026 | $11.28 | $11.43 | $10.64 | $10.66 | 239.47K |
| Aug 12, 2026 | $10.69 | $11.23 | $10.5546 | $11.20 | 159.71K |
| Aug 11, 2026 | $10.63 | $10.7295 | $10.55 | $10.64 | 137.92K |
| Aug 10, 2026 | $11.15 | $11.18 | $10.54 | $10.69 | 170.83K |
| Aug 7, 2026 | $10.74 | $11.26 | $10.575 | $11.15 | 319.63K |
| Aug 6, 2026 | $9.97 | $10.71 | $9.97 | $10.65 | 386.63K |
| Aug 5, 2026 | $10.175 | $10.29 | $9.865 | $9.995 | 335.16K |
| Aug 4, 2026 | $9.77 | $10.43 | $9.69 | $10.25 | 276.93K |
| Aug 3, 2026 | $10.16 | $10.18 | $9.87 | $10.11 | 154.11K |
Latest KROS news
The latest Smart Investors Daily articles mentioning KROS.
Stock researchCompany · Overview
KROS research
Overview
Company profile and research snapshot.
Company profile
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $102.60
- Implied upside
- —
- Analysts
- 17
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 4, 2026 | Leerink Partners | Outperform | — |
| Aug 4, 2026 | Wells Fargo | Overweight | — |
| Mar 5, 2026 | Wells Fargo | Overweight | — |
| Nov 28, 2025 | B of A Securities | Neutral | — |
| Nov 12, 2025 | Oppenheimer | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 3, 2026
Keros Therapeutics Reports Second Quarter 2026 Financial Results
LEXINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the quarter ended June 30, 2026. “We are excite
Benzinga · Aug 3, 2026
Keros Therapeutics Q2 EPS $(1.45) Misses $(1.34) Estimate
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.45) per share which missed the analyst consensus estimate of $(1.34) by 8.21 percent. This is a 90.79 percent decrease over losses of $(0.76) per share
Yahoo · Jul 30, 2026
Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda
LEXINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it will receive a $20 million development milestone payment under the terms of the license agreement of elriter
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
